CD34 and leukemia: This may be due to the use of granulocyte colony-stimulating factors and secondary infections in some leukemia patients, both of which may stimulate the proliferation of myeloid progenitor cells36–38, and therefore compromise the rationality of applying CD34+ myeloblasts as an indicator of the intrinsic ability of hematopoietic recovery in bone marrow.